Drugs / rHSV2hGM-CSF
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05070221 | Oct 2021 → Oct 2023 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 1 | NCT05068453 | Oct 2021 → Oct 2023 | metastatic melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHSV2hGM-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05070221 ↗ |
| Route | Other | “recombinant human GM-CSF herpes simplex virus（intratumoral injection）” NCT05068453 ↗ |